GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoTherapy Science Inc (TSE:4564) » Definitions » EV-to-FCF

OncoTherapy Science (TSE:4564) EV-to-FCF : (As of Dec. 12, 2024)


View and export this data going back to 2003. Start your Free Trial

What is OncoTherapy Science EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, OncoTherapy Science's Enterprise Value is 円7,322.7 Mil. OncoTherapy Science's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was 円0.0 Mil. Therefore, OncoTherapy Science's EV-to-FCF for today is .

The historical rank and industry rank for OncoTherapy Science's EV-to-FCF or its related term are showing as below:

TSE:4564' s EV-to-FCF Range Over the Past 10 Years
Min: -222.75   Med: -136.67   Max: -2.81
Current: -5.73

During the past 13 years, the highest EV-to-FCF of OncoTherapy Science was -2.81. The lowest was -222.75. And the median was -136.67.

TSE:4564's EV-to-FCF is ranked worse than
100% of 385 companies
in the Biotechnology industry
Industry Median: 8.82 vs TSE:4564: -5.73

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), OncoTherapy Science's stock price is 円31.00. OncoTherapy Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was 円-6.073. Therefore, OncoTherapy Science's PE Ratio (TTM) for today is At Loss.


OncoTherapy Science EV-to-FCF Historical Data

The historical data trend for OncoTherapy Science's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoTherapy Science EV-to-FCF Chart

OncoTherapy Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.58 -10.40 -4.53 -9.92 -3.29

OncoTherapy Science Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -3.29 -

Competitive Comparison of OncoTherapy Science's EV-to-FCF

For the Biotechnology subindustry, OncoTherapy Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's EV-to-FCF falls into.



OncoTherapy Science EV-to-FCF Calculation

OncoTherapy Science's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7322.679/0
=

OncoTherapy Science's current Enterprise Value is 円7,322.7 Mil.
OncoTherapy Science's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoTherapy Science  (TSE:4564) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

OncoTherapy Science's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=31.00/-6.073
=At Loss

OncoTherapy Science's share price for today is 円31.00.
OncoTherapy Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-6.073.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


OncoTherapy Science EV-to-FCF Related Terms

Thank you for viewing the detailed overview of OncoTherapy Science's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoTherapy Science Business Description

Traded in Other Exchanges
N/A
Address
11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.

OncoTherapy Science Headlines

No Headlines